Montara Therapeutics Powers Precision CNS Medicine with $4.8M Investment from Dogwood Therapeutics

Montara Therapeutics, a San Francisco–based precision-medicine neuroscience biotech startup, is excited to announce the successful closing of a funding round that raised $4,800,000.

This significant capital infusion marks a pivotal milestone for our company, which is dedicated to revolutionizing the treatment of central nervous system diseases.

Drawing on the deep expertise of our team—whose experience spans trailblazing biotech firms such as Mitokinin, Denali, and Soteria—we are uniquely positioned to address long-standing challenges in drug discovery.

Our specialized focus on developing enzyme activators and our pioneering work in mitophagy are setting new benchmarks in precision medicine and therapeutic efficacy.

The funds raised will be deployed toward accelerating our R&D efforts, advancing our pipeline for genetically validated targets, and enhancing our drug safety platforms.

With the support of a world-class Scientific Advisory Board, we plan to expand our research capabilities and fortify our infrastructure, enabling us to bring innovative, patient-focused therapies to market faster.

This investment not only underscores the strength of our scientific platform and strategic vision but also reaffirms the market’s confidence in our ability to transform neuroscience treatment paradigms.

As we continue to push the boundaries of precision medicine, this funding round serves as both an endorsement of our mission and a catalyst for our next phase of growth.

We are committed to leveraging these resources to explore novel biochemical pathways and deliver groundbreaking treatments for patients facing severe CNS disorders.

With our cutting-edge approach and dedicated team, Montara Therapeutics is poised to make a lasting impact on the future of neurotherapeutics.